Annalisa Aratari

Annalisa Aratari

Auto-generated profile, based on publicly available information

Annalisa Aratari

Gastroenterology & Hepatology Unit, S. Filippo Neri Hospital, Rome, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Digestive and Liver Disease
Verified
Journal Article
Closed access
AAA. Aratari
A. Aratari
CPC. Papi
C. Papi
VCV. Clemente
V. Clemente
AMA. Moretti
A. Moretti
RLR. Luchetti
R. Luchetti
RCR. Caprilli
R. Caprilli

10 September 2007 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AAA. Aratari
A. Aratari
CPC. Papi
C. Papi
GLG. Leandro
G. Leandro
AVAngelo Viscido
Angelo Viscido
LCL. Capurso
L. Capurso
RCR. Caprilli
R. Caprilli
Summary: Background  Surgical resection is almost inevitable in Crohn’s disease. Surgery is usually performed for refractory or complicated disease: no studies appear to have been carried out, so far, to evaluate the potential benefits of performing surgery early in the course of the disease.Aim  To compare the long‐term course of Crohn’s disease following ileo‐caecal resection performed at the time of diagnosis (early surgery) or during the course of the disease (late surgery).Patients and methods  Overall 207 patients with ileo‐caecal Crohn’s disease at their first resection were reviewed: 83 patients underwent surgery at the time of diagnosis (early surgery), while 124 underwent surgery 54.2 months (range 1–438) after diagnosis (late surgery). The mean follow‐up after surgery was 147 months (range 12–534). The primary endpoint was clinical recurrence, defined as need for corticosteroids for symptomatic disease in the presence of endoscopic and/or radiologic recurrence. Secondary endpoints were need for immunosuppressants and surgical recurrence. Statistical analysis: Kaplan–Meier survival method and Cox proportional hazards regression model.Results  Within 10 years after surgery, the cumulative probability of clinical recurrence was significantly lower in the early surgery group (Log Rank test P = 0.01). A trend was observed regarding the need for immunosuppressants (P = 0.05). No difference was observed regarding surgical recurrence. At multivariate analysis, early surgery was the only independent variable associated with a reduced risk of clinical recurrence (Hazard ratio, HR = 0.57; 95% CI 0.35 to 0.92, P = 0.02), but not with need for immunosuppressants and surgical recurrence (HR = 0.51; 95% CI 0.20 to 1.30, P = 0.15; HR = 0.66; 95% CI 0.33 to 1.35, P = 0.25, respectively).Conclusion  Early surgery prolongs clinical remission compared to surgery performed during the course of the disease, but the natural history of disease is not modified.

1 August 2014 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
RMRita Monterubbianesi
Rita Monterubbianesi
AAAnnalisa Aratari
Annalisa Aratari
Alessandro ArmuzziAlessandro Armuzzi
Alessandro Armuzzi
MDMarco Daperno
Marco Daperno
Livia BianconeLivia Biancone
Livia Biancone
AKAnna Kohn
Anna Kohn
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.

1 May 2006 in Digestive and Liver Disease
Verified
Journal Article
Closed access
AAA. Aratari
A. Aratari
CPC. Papi
C. Papi
BGB. Galletti
B. Galletti
EAE. Angelucci
E. Angelucci
AVAngelo Viscido
Angelo Viscido
RCR. Caprilli
R. Caprilli

11 June 2004 in Gut
Verified
Journal Article
Closed access
PDF file
AVAngelo Viscido
Angelo Viscido
AAA Aratari
A Aratari
MPM Pimpo
M Pimpo
VDV D’oVidio
V D’oVidio
GFG Frieri
G Frieri
MCM Crobu
M Crobu